Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028517 | 0.98 | CA12 (0.56) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL8256720 | 0.89 | HRH3 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL11025226 | 0.87 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2KDM4EMAPTCYP1A2 | |
| SCHEMBL11027232 | 0.86 | SMN1; SMN2 (0.54) | ALDH1A1GAASMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL13661591 | 0.84 | MAPT (0.70) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL4283848 | 0.84 | ALDH1A1 (0.81) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL84849 | 0.82 | ALDH1A1 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18629170 | 0.82 | CA12 (0.56) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL20249046 | 0.82 | CA12 (0.56) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL11026192 | 0.82 | HDAC2 (0.51) | ALDH1A1GAASMN1; SMN2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-08 | — | — | US | disclosed |
| US-20070037822-A1 | Azinone and diazinone V3 inhibitors for depression and stress disorders | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037822-A1 | Azinone and diazinone V3 inhibitors for depression and stress disorders | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2006133242-A2 | AZINONE AND DIAZINONE V3 INHIBITORS FOR DEPRESSION AND STRESS DISORDERS | PHARMACOPEIA, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060135553-A1 | Imidazole derivatives | PHENOMIX CORPORATION | 2006-06-22 | — | — | US | disclosed |
| WO-2006050162-A2 | IMIDAZOLE DERIVATIVES | PHENOMIX CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-0040793-B1 | NOVEL QUINAZOLINE-DIONE COMPOUNDS, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | Ishikawa, Masayuki (JP) | 1985-08-28 | — | — | EP | disclosed |
| US-4405623-A | HYPOTENSIVE AGENTS, VASODILATORS | MASAYUKI ISHIKAWA (JP) | 1983-09-20 | — | — | US | disclosed |
| EP-0040793-A1 | Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof | Ishikawa, Masayuki (JP) | 1981-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135553-A1 | Imidazole derivatives | FLT4, NOS2, FLT1 | CA12 4674/4885CA1 4663/4885CA2 2855/4885 |
| US-20070037822-A1 | Azinone and diazinone V3 inhibitors for depression and stress disorders | HTR3C, HTR3A, AZI2 | CA12 4808/4885CA1 3982/4885CA2 4338/4885 |
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, SARS1, ACE | CA12 2497/4885CA1 4450/4885CA2 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.